<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03350308</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-363</org_study_id>
    <secondary_id>2014-A01538-39</secondary_id>
    <nct_id>NCT03350308</nct_id>
  </id_info>
  <brief_title>Prediction of Risk of Hypotension in Hemodialysis</brief_title>
  <acronym>IMHOTEP</acronym>
  <official_title>Prediction of Risk of Hypotension in Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de dialyse AURA Plaisance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre d’Hémodialyse Pôle Santé République</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Service de Néphrologie et Hémodialyse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to establish a statistical predictive model of the risk of
      intradialytic hypotension during hemodialysis (HD) or hemodiafiltration (HDF) sessions based
      on the measurement of residual blood volume and excess extracellular hydration. The secondary
      objective is to study the impact of dysfunction in the mechanisms of compensation for
      decreased blood volume (heart disease, neuropathy, drugs) on the risk of intradialytic
      hypotension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study is 4 weeks for each patient. It will first be carried out a
      spectral analysis of heart rate variability (CHU of Clermont Ferrand only) and a measurement
      of intracellular and extracellular volumes by bioimpedancemetry. During the next 9 sessions,
      the decrease in the VSR will be recorded using an optical haematocrit measurement system.
      Blood pressure and heart rate will be measured every 30 minutes using an automatic blood
      pressure monitor and whenever the patient's nurse deems it necessary.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk of PAS with symptom</measure>
    <time_frame>at 3 week</time_frame>
    <description>The primary outcome will be the risk of a decrease in PAS of more than 20 mmHg or a decrease in WFP of at least 10 mmHg associated with clinical symptomatology (vertigo, malaise, nausea or cramps)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk of PAS with symptom without symptom</measure>
    <time_frame>at 3 week</time_frame>
    <description>The risk of a decrease in PAS of more than 20 mmHg or a decrease in WFP of at least 10 mmHg (with or without symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk of reduction of PAS below 90 mmHg (with or without symptoms)</measure>
    <time_frame>at 3 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk of isolated symptoms caracterized by vertigo, discomfort, nausea or cramps</measure>
    <time_frame>at 3 week</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronical Kidney Disease</condition>
  <condition>Hypotension</condition>
  <condition>Residual Blood Volume</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Patients with chronic end-stage renal failure</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hemodialysis</intervention_name>
    <description>The main objective is to establish a statistical predictive model of the risk of intradialytic hypotension during hemodialysis (HD) or hemodiafiltration (HDF) sessions based on the measurement of residual blood volume and excess extracellular hydration</description>
    <arm_group_label>Patients with chronic end-stage renal failure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic end-stage renal failure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old minimum patients

          -  Patients with chronic end-stage renal failure

          -  Patients treated with hemodialysis for at least 3 months, 3 times a week (duration of
             sessions 3 to 5 hours)

          -  Patients with at least 2 episodes of intradialytic hypotension in the last month

          -  Patients without acute events within 3 months prior to inclusion

          -  Patients affiliated with or receiving social security benefits

        Exclusion Criteria:

          -  Hemoglobin levels outside the limits of measurement (&lt;7 g/L or &gt;15g/L)

          -  Patients whose probable survival does not exceed 6 months

          -  Patients with progressive acute pathology

          -  Patient following another research protocol that may influence results

          -  Patients with psychiatric pathology or cognitive impairments that make them unable to
             give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien ANIORT</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>0473751195</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Julien ANIORT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline CREPUT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc BOUILLER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Myriam ISNARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

